Ibutilide: A new class III antiarrhythmic agent

Jacquelyn S. Cropp, Ellen G. Antal, Robert Talbert

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Ibutilide fumarate is a new antiarrhythmic agent recently approved for the conversion of atrial flutter (AFI) and atrial fibrillation (AF) to normal sinus rhythm. A class III agent in the Vaughan Williams classification system, ibutilide prolongs cardiac repolarization by activating a slow inward, predominantly sodium current. An alternative or additive mechanism to prolong repolarization may be blockade of the outward delayed rectifier potassium rapid current. Ibutilide is administered intravenously, and approximately 40% of the drug in serum is protein bound. It is eliminated through hepatic metabolism by undefined enzyme systems, and it appears that none of the metabolites contributes significantly to antiarrhythmic activity. The elimination half-life of ibutilide ranges from 2-12 hours. When administered by 10-minute infusion, ibutilide 1 mg (approximately 0.015 mg/kg) resulted in conversion to sinus rhythm in 24-58% of patients with AFI and 20-32% with AE compared with about 5% for placebo. Administering a second dose of 0.5-1 mg improved the overall response rates to approximately 75% and 45%, respectively. In randomized comparative trials, ibutilide was more effective than sotalol in converting AFI (70% vs 19%) and AF (44% vs 11%) and more effective than procainamide (76% vs 12% and 51% vs 20%, respectively). The time to conversion in most trials was usually 20-30 minutes. Nausea is the most common noncardiac adverse effect (< 2%). Nonsustained and sustained polymorphic ventricular tachycardia occurred in 2.7-6.7% and 1.7% of patients, respectively.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalPharmacotherapy
Volume17
Issue number1
StatePublished - Jan 1997

Fingerprint

Atrial Fibrillation
Sotalol
Procainamide
Atrial Flutter
Ventricular Tachycardia
Nausea
Half-Life
ibutilide
Blood Proteins
Potassium
Sodium
Placebos
Liver
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Cropp, J. S., Antal, E. G., & Talbert, R. (1997). Ibutilide: A new class III antiarrhythmic agent. Pharmacotherapy, 17(1), 1-9.

Ibutilide : A new class III antiarrhythmic agent. / Cropp, Jacquelyn S.; Antal, Ellen G.; Talbert, Robert.

In: Pharmacotherapy, Vol. 17, No. 1, 01.1997, p. 1-9.

Research output: Contribution to journalArticle

Cropp, JS, Antal, EG & Talbert, R 1997, 'Ibutilide: A new class III antiarrhythmic agent', Pharmacotherapy, vol. 17, no. 1, pp. 1-9.
Cropp JS, Antal EG, Talbert R. Ibutilide: A new class III antiarrhythmic agent. Pharmacotherapy. 1997 Jan;17(1):1-9.
Cropp, Jacquelyn S. ; Antal, Ellen G. ; Talbert, Robert. / Ibutilide : A new class III antiarrhythmic agent. In: Pharmacotherapy. 1997 ; Vol. 17, No. 1. pp. 1-9.
@article{2ce2b9417ace461b9613a1c0d405bb68,
title = "Ibutilide: A new class III antiarrhythmic agent",
abstract = "Ibutilide fumarate is a new antiarrhythmic agent recently approved for the conversion of atrial flutter (AFI) and atrial fibrillation (AF) to normal sinus rhythm. A class III agent in the Vaughan Williams classification system, ibutilide prolongs cardiac repolarization by activating a slow inward, predominantly sodium current. An alternative or additive mechanism to prolong repolarization may be blockade of the outward delayed rectifier potassium rapid current. Ibutilide is administered intravenously, and approximately 40{\%} of the drug in serum is protein bound. It is eliminated through hepatic metabolism by undefined enzyme systems, and it appears that none of the metabolites contributes significantly to antiarrhythmic activity. The elimination half-life of ibutilide ranges from 2-12 hours. When administered by 10-minute infusion, ibutilide 1 mg (approximately 0.015 mg/kg) resulted in conversion to sinus rhythm in 24-58{\%} of patients with AFI and 20-32{\%} with AE compared with about 5{\%} for placebo. Administering a second dose of 0.5-1 mg improved the overall response rates to approximately 75{\%} and 45{\%}, respectively. In randomized comparative trials, ibutilide was more effective than sotalol in converting AFI (70{\%} vs 19{\%}) and AF (44{\%} vs 11{\%}) and more effective than procainamide (76{\%} vs 12{\%} and 51{\%} vs 20{\%}, respectively). The time to conversion in most trials was usually 20-30 minutes. Nausea is the most common noncardiac adverse effect (< 2{\%}). Nonsustained and sustained polymorphic ventricular tachycardia occurred in 2.7-6.7{\%} and 1.7{\%} of patients, respectively.",
author = "Cropp, {Jacquelyn S.} and Antal, {Ellen G.} and Robert Talbert",
year = "1997",
month = "1",
language = "English (US)",
volume = "17",
pages = "1--9",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Ibutilide

T2 - A new class III antiarrhythmic agent

AU - Cropp, Jacquelyn S.

AU - Antal, Ellen G.

AU - Talbert, Robert

PY - 1997/1

Y1 - 1997/1

N2 - Ibutilide fumarate is a new antiarrhythmic agent recently approved for the conversion of atrial flutter (AFI) and atrial fibrillation (AF) to normal sinus rhythm. A class III agent in the Vaughan Williams classification system, ibutilide prolongs cardiac repolarization by activating a slow inward, predominantly sodium current. An alternative or additive mechanism to prolong repolarization may be blockade of the outward delayed rectifier potassium rapid current. Ibutilide is administered intravenously, and approximately 40% of the drug in serum is protein bound. It is eliminated through hepatic metabolism by undefined enzyme systems, and it appears that none of the metabolites contributes significantly to antiarrhythmic activity. The elimination half-life of ibutilide ranges from 2-12 hours. When administered by 10-minute infusion, ibutilide 1 mg (approximately 0.015 mg/kg) resulted in conversion to sinus rhythm in 24-58% of patients with AFI and 20-32% with AE compared with about 5% for placebo. Administering a second dose of 0.5-1 mg improved the overall response rates to approximately 75% and 45%, respectively. In randomized comparative trials, ibutilide was more effective than sotalol in converting AFI (70% vs 19%) and AF (44% vs 11%) and more effective than procainamide (76% vs 12% and 51% vs 20%, respectively). The time to conversion in most trials was usually 20-30 minutes. Nausea is the most common noncardiac adverse effect (< 2%). Nonsustained and sustained polymorphic ventricular tachycardia occurred in 2.7-6.7% and 1.7% of patients, respectively.

AB - Ibutilide fumarate is a new antiarrhythmic agent recently approved for the conversion of atrial flutter (AFI) and atrial fibrillation (AF) to normal sinus rhythm. A class III agent in the Vaughan Williams classification system, ibutilide prolongs cardiac repolarization by activating a slow inward, predominantly sodium current. An alternative or additive mechanism to prolong repolarization may be blockade of the outward delayed rectifier potassium rapid current. Ibutilide is administered intravenously, and approximately 40% of the drug in serum is protein bound. It is eliminated through hepatic metabolism by undefined enzyme systems, and it appears that none of the metabolites contributes significantly to antiarrhythmic activity. The elimination half-life of ibutilide ranges from 2-12 hours. When administered by 10-minute infusion, ibutilide 1 mg (approximately 0.015 mg/kg) resulted in conversion to sinus rhythm in 24-58% of patients with AFI and 20-32% with AE compared with about 5% for placebo. Administering a second dose of 0.5-1 mg improved the overall response rates to approximately 75% and 45%, respectively. In randomized comparative trials, ibutilide was more effective than sotalol in converting AFI (70% vs 19%) and AF (44% vs 11%) and more effective than procainamide (76% vs 12% and 51% vs 20%, respectively). The time to conversion in most trials was usually 20-30 minutes. Nausea is the most common noncardiac adverse effect (< 2%). Nonsustained and sustained polymorphic ventricular tachycardia occurred in 2.7-6.7% and 1.7% of patients, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0031026491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031026491&partnerID=8YFLogxK

M3 - Article

C2 - 9017761

AN - SCOPUS:0031026491

VL - 17

SP - 1

EP - 9

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -